These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15986340)

  • 41. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases.
    Hallegua DS; Weisman MH
    Ann Rheum Dis; 2002 Nov; 61(11):960-7. PubMed ID: 12379516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erosion healing in rheumatoid arthritis after anakinra treatment.
    Rau R; Sander O; Wassenberg S
    Ann Rheum Dis; 2003 Jul; 62(7):671-3. PubMed ID: 12810433
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of recombinant interleukin-1-receptor antagonist.
    Barriere SL; Pribble JP
    Am J Hosp Pharm; 1994 May; 51(9):1253, 1257. PubMed ID: 8042646
    [No Abstract]   [Full Text] [Related]  

  • 45. Interleukin-I antagonists.
    Dower SK; Fanslow W; Jacobs C; Waugh S; Sims JE; Widmer MB
    Ther Immunol; 1994 Apr; 1(2):113-22. PubMed ID: 7584483
    [No Abstract]   [Full Text] [Related]  

  • 46. Alternative views on the effects of recombinant interleukin-1-receptor antagonist.
    Vance-Bryan K; Hoey LL; Joslin SM
    Am J Hosp Pharm; 1994 Nov; 51(21):2724-7. PubMed ID: 7710539
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist].
    Rau R; Sander O; Musikic P
    Z Rheumatol; 1998 Oct; 57(5):312-9. PubMed ID: 9864837
    [No Abstract]   [Full Text] [Related]  

  • 48. Moraxella catarrhalis-induced septic arthritis of a prosthetic knee joint in a patient with rheumatoid arthritis treated with anakinra: comment on the article by Schiff et al.
    Leonardou A; Giali S; Daoussis D; Siambi V; Gogos H; Liossis SN
    Arthritis Rheum; 2005 Apr; 52(4):1337; author reply 1338. PubMed ID: 15818660
    [No Abstract]   [Full Text] [Related]  

  • 49. [Phlegmon of the forearm due to therapy with Anakinra (interleukin-1 receptor-antagonist)].
    Gaulke R
    Z Rheumatol; 2003 Dec; 62(6):566-9. PubMed ID: 14685719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (Anakinra).
    Turesson C; Riesbeck K
    J Rheumatol; 2004 Sep; 31(9):1876. PubMed ID: 15338480
    [No Abstract]   [Full Text] [Related]  

  • 51. [Remission--therapy goal in rheumatoid arthritis].
    Z Rheumatol; 2007 Feb; 66(1):2 p following 87. PubMed ID: 17896425
    [No Abstract]   [Full Text] [Related]  

  • 52. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra).
    Vounotrypidis P; Sakellariou GT; Zisopoulos D; Berberidis C
    Rheumatology (Oxford); 2006 Apr; 45(4):491-2. PubMed ID: 16510529
    [No Abstract]   [Full Text] [Related]  

  • 53. Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonist.
    Wendling D; Aubin F
    Joint Bone Spine; 2006 May; 73(3):333-4. PubMed ID: 16563838
    [No Abstract]   [Full Text] [Related]  

  • 54. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS).
    Ramos E; Aróstegui JI; Campuzano S; Rius J; Bousoño C; Yagüe J
    Rheumatology (Oxford); 2005 Aug; 44(8):1072-3. PubMed ID: 15840596
    [No Abstract]   [Full Text] [Related]  

  • 55. Intracellular IL-1 alpha in fibroblasts as a possible endogenous mediator of joint damage in rheumatoid arthritis.
    Apte RN
    Isr J Med Sci; 1997 Apr; 33(4):285-8. PubMed ID: 9347881
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Successful treatment of clinical manifestations of Muckle-Wells syndrome with anakinra].
    Dybowski F; Jakobs B; Altmeyer P; Braun J
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1863-6. PubMed ID: 16915547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.
    Fleischmann R; Stern R; Iqbal I
    Expert Opin Biol Ther; 2004 Aug; 4(8):1333-44. PubMed ID: 15268666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the interleukin-15 system in rheumatoid arthritis.
    Waldmann TA
    Arthritis Rheum; 2005 Sep; 52(9):2585-8. PubMed ID: 16142738
    [No Abstract]   [Full Text] [Related]  

  • 60. Arthritis: is the cure in your genes?
    Herndon JH; Robbins PD; Evans CH
    J Bone Joint Surg Am; 1999 Feb; 81(2):152-7. PubMed ID: 10073578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.